Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Penumbra reports strong Q3 earnings, eyes global blood clot market

Penumbra's Q3 2024 earnings call showcased robust financial performance, driven by revenue growth and margin expansion. The company's innovative technologies and regulatory milestones position it for future success in the blood clot treatment market. While facing challenges in sustaining growth and navigating market dynamics, Penumbra has opportunities to capitalize on its strengths and drive global transformation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Penumbra (PEN) delivered earnings and revenue surprises of 37.50% and 6.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Reports Q2 Loss, Tops Revenue Estimates

Shares of Penumbra (NYSE:PEN) fell 0.25% after the company reported Q2 results. Quarterly Results Earnings per share fell 211.11% year over year to ($0.30), which beat the estimate of ($0.39).

Penumbra: Q2 Earnings Insights

ALAMEDA, Calif., Aug. 3, 2020 /PRNewswire/ -- Penumbra, Inc.

Penumbra, Inc. Reports Second Quarter 2020 Financial Results

ALAMEDA, Calif., July 29, 2020 /PRNewswire/ -- Penumbra, Inc.

Penumbra, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Penumbra (PEN) Q2 Earnings Expected to Decline

A Relative Strength Rating upgrade for Penumbra shows improving technical performance.

Penumbra Earns Relative Strength Rating Upgrade; Hits Key Benchmark

ALAMEDA, Calif., May 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, 2020. Event: William Blair 40th Annual Growth Stock Conference Date:...

Penumbra, Inc. to Present at the William Blair 40th Annual Growth Stock Conference

ALAMEDA, Calif., May 27, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the pricing of an underwritten public offering of 753,012 shares of its common stock at a price to the public of $166.00 per share. All of...

Penumbra, Inc. Announces Pricing of Offering of Common Stock

ALAMEDA, Calif., May 15, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that the format for its 2020 Annual Meeting of Stockholders (the "Annual Meeting") has been changed from an in-person meeting to a virtual-only meeting at the previously announced date and time of...

Penumbra, Inc. Announces Virtual 2020 Annual Meeting of Stockholders

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q1 2020 Results - Earnings Call Transcript

AmerisourceBergen

Becton, Dickinson and Co.

Insulet

Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.

Medical Products Stock Earnings on May 7: BDX, ABC & More

Penumbra (PEN) closed at $181.06 in the latest trading session, marking a +0.93% move from the prior day.

Penumbra (PEN) Gains But Lags Market: What You Should Know

Penumbra Clears Key Benchmark, Hitting 90-Plus RS Rating

Penumbra (PEN) registers balanced segmental growth across all geographies in Q4.

Penumbra (PEN) Q4 Earnings Beat Estimates, Margins Expand

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q4 2019 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of 22.22% and 2.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Tops Q4 Earnings and Revenue Estimates

PayPal

AstraZeneca

Mondelez

World Wrestling Entertainment

Canaccord called Penumbra a "top, long-term" pick and said the stock has everything an investor should want.

Here are some of the best analyst calls of the week on Wall Street including PayPal, WWE

Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.

Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates

Penumbra's (PEN) CEO Adam Elsesser on Q3 2019 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of 38.89% and 4.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Beats Q3 Earnings and Revenue Estimates

Abbott Labs

Cardinal Health

Varian Medical Systems

DENTSPLY SIRONA

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth

Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

Penumbra Enrolls First Patient for Study on Coronary Vessels

EVP and Chief Business Officer of Penumbra Inc (30-Year Financial, Insider Trades) Lynn Rothman (insider trades) sold 5,000 shares of PEN on 08/19/2019 at an average price of $144.66 a share.

Penumbra Inc (PEN) EVP and Chief Business Officer Lynn Rothman Sold $723,300 of Shares

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q2 2019 Results - Earnings Call Transcript

News for Penumbra Stock (PEN)